H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

Soleno Therapeutics (SLNO) stock jumped over 32% in yesterday’s after-hours trading. The surge came after the company ...

The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) shares were up 3.9% during trading on Friday after Stifel Nicolaus ...

Soleno Therapeutics, Inc.’s SLNO share price has surged by 35.80%, which has investors questioning if this is right time to ...

Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, ...